If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
=== Regulation === In order to ensure proper functioning, Wnt signaling is constantly regulated at several points along its signaling pathways. For example, Wnt proteins are palmitoylated. The protein porcupine mediates this process, which means that it helps regulate when the Wnt ligand is secreted by determining when it is fully formed. Secretion is further controlled with proteins such as GPR177 (wntless) and evenness interrupted and complexes such as the retromer complex. Upon secretion, the ligand can be prevented from reaching its receptor through the binding of proteins such as the stabilizers Dally and glypican 3 (GPC3), which inhibit diffusion. In cancer cells, both the heparan sulfate chains and the core protein of GPC3 are involved in regulating Wnt binding and activation for cell proliferation. Wnt recognizes a heparan sulfate structure on GPC3, which contains IdoA2S and GlcNS6S, and the 3-O-sulfation in GlcNS6S3S enhances the binding of Wnt to the heparan sulfate glypican. A cysteine-rich domain at the N-lobe of GPC3 has been identified to form a Wnt-binding hydrophobic groove including phenylalanine-41 that interacts with Wnt. Blocking the Wnt binding domain using a nanobody called HN3 can inhibit Wnt activation. At the Fz receptor, the binding of proteins other than Wnt can antagonize signaling. Specific antagonists include Dickkopf (Dkk), Wnt inhibitory factor 1 (WIF-1), secreted Frizzled-related proteins (SFRP), Cerberus, Frzb, Wise, SOST, and Naked cuticle. These constitute inhibitors of Wnt signaling. However, other molecules also act as activators.
A lobotomy (from Greek λοβός (lobos) 'lobe' and τομή (tomē) 'cut, slice') or leucotomy is a discredited form of neurosurgical treatment for psychiatric disorder or neurological disorder (e.g. epilepsy, depression) that involves severing connections in the brain's prefrontal cortex. The surgery severs most of the connections to and from the prefrontal cortex, and the anterior part of the frontal lobes of the brain. From the 1930s until the 1970s, the treatment was used for handling psychiatric disorders as a mainstream procedure in some countries. A preoccupation with the ability to work and personal responsibility over patient well-being were contributing factors to the prevalence of lobotomies in the United States. The originator of the procedure, Portuguese neurologist António Egas Moniz, shared the Nobel Prize for Physiology or Medicine of 1949 for the "discovery of the therapeutic value of leucotomy in certain psychoses", although the awarding of the prize has been subject to controversy. The procedure was modified and championed by Walter Freeman, who performed the first lobotomy at a mental hospital in the United States in 1936. Its use increased dramatically from the early 1940s and into the 1950s; by 1951, almost 20,000 lobotomies had been performed in the US and proportionally more in the United Kingdom. More lobotomies were performed on women than on men: a 1951 study found that nearly 60% of American lobotomy patients were women, and limited data shows that 74% of lobotomies in Ontario from 1948 to 1952 were performed on female patients.
Beginning in the 1st millennium BCE, groups of Amerindians including the Muisca, Zenú, Quimbaya, and Tairona developed the political system of cacicazgos with a pyramidal structure of power headed by caciques. The Muisca inhabited mainly the area of what is now the Departments of Boyacá and Cundinamarca high plateau (Altiplano Cundiboyacense) where they formed the Muisca Confederation. They farmed maize, potato, quinoa, and cotton, and traded gold, emeralds, blankets, ceramic handicrafts, coca and especially rock salt with neighboring nations. The Tairona inhabited northern Colombia in the isolated mountain range of Sierra Nevada de Santa Marta. The Quimbaya inhabited regions of the Cauca River Valley between the Western and Central Ranges of the Colombian Andes. Most of the Amerindians practiced agriculture and the social structure of each Indigenous community was different. Some groups of Indigenous people such as the Caribs lived in a state of permanent war, but others had less bellicose attitudes. During the 1200s, Malayo-Polynesians and Amerindians in Colombia made contact, thereby spreading Indigeous Amerindian genetics from Precolonial Colombia to some Pacific Ocean islands. The coconuts found in Colombia which originally come from the Philippines originate from this Precolombian exchange.
== Research and career == Dunn-Walters has over a hundred primary research publications. She studies B cell development in disease, and how the immune system changes during ageing. She has developed new characterisation techniques to understand immune responses, including single-cell and repertoire approaches. She discovered IgM memory B cells in the spleen, that the older immune system has a less diverse repertoire of B cells, that there are at least 10 different types of B cells, that different types of B cells may have different repertoires and therefore be responding to different stimuli. She works in collaboration with computer scientists and together they have produced online tools for repertoire analysis. More recently, the development of new tools for distinguishing between productive and sterile transcripts of Ig constant region genes in B cells has shown that B cells become primed for Immunoglobulin class switching in a stage before they actually switch. She is part of the CARINA (Catalyst Reducing Immune Ageing) Network, a collective which looks to understand how ageing impacts the immune system and vice versa. Dunn-Walters has served on grants awarding and strategy committees for funding bodies such as the UK Research and Innovation (UKRI) MRC and BBSRC, Research Council of Norway, Fondazione Cariplo Italy. She is a member of the British Society for Research on Ageing where she has previously served on the board and as Programme Secretary.
== Awards == 1977, Young Investigator award, National Institutes of Health (NIH) 1979, Research Career Development Award, NIH 1983, Recognition Award for Young Scholars, American Association of University Women 1987, John J. Abel Award in Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET) Limbird was the second woman to receive this award, the first being Eva King Killam in 1954. 1989, MERIT Award, NIH 1994, Distinguished Investigator Award, National Alliance for Research on Schizophrenia and Depression (NARSAD, now Brain & Behavior Research Foundation). 1998, Distinguished Alumni Award, College of Wooster 2004, Goodman and Gilman Award in Drug Receptor Pharmacology, ASPET 2013, Julius Axelrod Award, ASPET.
Sources: en.wikipedia.org
Aperture Hand Lab is a roomscale VR video game co-developed by Canadian studio Cloudhead Games and Valve, released free for Windows on June 25, 2019. It is a tech demo set in the Portal universe that showcases the functions of the hand, knuckle, and finger tracking technology used by the Valve Index.
=== Final tour and death in New York === Thomas left Laugharne on 9 October 1953 on the first leg of his fourth trip to America. He called on his mother, Florence, to say goodbye: "He always felt that he had to get out from this country because of his chest being so bad." Thomas had suffered from chest problems for most of his life, though they began in earnest soon after he moved in May 1949 to the Boat House at Laugharne—the "bronchial heronry", as he called it. Within weeks of moving in, he visited a local doctor, who prescribed medicine for both his chest and throat. While waiting in London before his flight, Thomas stayed with the comedian Harry Locke and worked on Under Milk Wood. Locke noted that Thomas was having trouble with his chest, "terrible" coughing fits that made him go purple in the face. He was also using an inhaler to help his breathing. There were reports, too, that Thomas was also having blackouts. His visit to the BBC producer Philip Burton, a few days before he left for New York, was interrupted by a blackout. On his last night in London, he had another in the company of his fellow poet Louis MacNeice. Thomas arrived in New York on 20 October 1953 to undertake further performances of Under Milk Wood, organised by John Brinnin, his American agent and Director of the Poetry Centre. Brinnin did not travel to New York but remained in Boston to write. He handed responsibility to his assistant, Liz Reitell. She met Thomas at Idlewild Airport and was shocked at his appearance.
In Virus (2019), directed by Aashiq Abu, Kallingal played nurse Akhila, a character based on Lini Puthussery — the nurse who died treating Kerala's first patient in the 2018 Nipah virus outbreak. Lini Puthussery's husband, who attended a screening of the film, said that Kallingal's portrayal was faithful and delivered "a flawless performance as Lini". Kallingal co-produced the film with Aashiq Abu under their production banner OPM Cinemas. Sowmya Rajendran described her performance as "expressive". In the 2021 film Santhoshathinte Onnam Rahasyam, directed by Don Palathara, Kallingal played an entertainment journalist opposite Jitin Puthenchery. Baradwaj Rangan described her performance as "terrific". The film won her Best Actress at the Diorama International Film Festival. In 2023 she appeared in Neelavelicham, a horror drama co-produced with Aashiq Abu. In 2025, Kallingal starred in Theatre, written and directed by Sajin Baabu, playing Meera, a woman who has lived an isolated life on a coastal Kerala island alongside her elderly mother. The film explores the conflict between traditional belief and modern science. The film had its world premiere at the Eurasian Bridge International Film Festival in Yalta on 9 October 2025, before its theatrical release on 16 October 2025. The role was physically demanding; director Sajin Baabu noted that Kallingal spent several hours atop a coconut tree for a single scene and completed multiple retakes despite sustaining bruises.
DCPIP (blue) + H+ → DCPIPH (pink) DCPIPH (pink) + vitamin C → DCPIPH2 (colorless) In this titration, when all the ascorbic acid in the solution has been used up, there will not be any electrons available to reduce the DCPIPH and the solution remains pink due to the DCPIPH. The end point is a pink color that persists for 10 seconds or more, if there is not enough ascorbic acid to reduce all of the DCPIPH. Pharmacological experiments suggest that DCPIP may serve as a pro-oxidant chemotherapeutic targeting human cancer cells in an animal model of human melanoma; DCPIP-induced cancer cell death occurs by depletion of intracellular glutathione and upregulation of oxidative stress.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.